Crism Therapeutics: Clinical Trial Update
The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.
13 August 2026
CRISM Therapeutics Corporation
("CRISM", "CRISM Therapeutics" or the "Company")
Clinical Trial Update
Site Initiation Visit Complete
CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, confirms that the Site Initiation Visit at the lead NHS clinical trial site has now completed successfully.
The Company is working closely with the clinical site, NHS Trust and its clinical partners to enable patient recruitment to commence in the coming weeks.
The Phase II study will evaluate irinotecan ChemoSeed®, the Company's proprietary implantable drug delivery technology designed to provide sustained, localised delivery of irinotecan directly into the tumour margin following surgical resection of a glioblastoma tumour.
-Ends-
Enquiries:
Company
Nomad and Broker
Financial PR
CRISM Therapeutics Corporation
S.P. Angel Corporate Finance LLP
Burson Buchanan
Andrew Webb, Executive Chairman
Chris McConville, CSO
David Hignell
Vadim Alexandre
Adam Cowl
Henry Harrison Topham
Jamie Hooper
CRISM@buchanancomms.co.uk
via Burson Buchanan
+44 (0) 20 3470 0470
+44 (0) 20 7466 5000
About CRISM Therapeutics Corporation
CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.
ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.
For more information please visit: https://www.crismtherapeutics.com/
The Company's LEI is 213800XFW6MKVCHHPW88.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDUPDPTMFTMTJBBMF
